OptimizeRx
OPRX
127 hedge funds and large institutions have $85.2M invested in OptimizeRx in 2026 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 48 increasing their positions, 28 reducing their positions, and 30 closing their positions.
288% more call options, than puts
Call options by funds: $1.32M | Put options by funds: $340K
71% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 28
0.54% more ownership
Funds ownership: 71.59% → 72.13% (+0.54%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 30
2% less funds holding
Funds holding: 129 → 127 (-2)
48% less capital invested
Capital invested by funds: $164M → $85.2M (-$78.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$2.15M |
| 2 |
ICM
Invenomic Capital Management
Boston,
Massachusetts
|
+$2.13M |
| 3 |
RA
Royce & Associates
New York
|
+$1.91M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$1.86M |
| 5 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$1.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCGI
Next Century Growth Investors
Plymouth,
Minnesota
|
-$6.2M |
| 2 |
GIPM
G2 Investment Partners Management
New York
|
-$3.8M |
| 3 |
MHP
Manatuck Hill Partners
Westport,
Connecticut
|
-$3.46M |
| 4 |
Russell Investments Group
London,
United Kingdom
|
-$1.52M |
| 5 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$1.44M |
OPRX Hedge Fund Activity: Q1 2026 in Review
127 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in OptimizeRx (OPRX) for Q1 2026, worth a combined $85.2M — down 48% from $164M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of OPRX and 29 opened new positions — a net loss of 1 holder — while 28 trimmed existing stakes and 48 added.
The largest buyer was Goldman Sachs, adding an estimated $2.15M. The largest seller was Next Century Growth Investors, exiting entirely with an estimated $6.2M sold.
- 127 institutional investors held OptimizeRx (OPRX) as of Q1 2026, down from 129 in Q4 2025.
- Funds reported $85.2M of OptimizeRx stock for Q1 2026, down 48% quarter-over-quarter.
- 29 funds opened new OptimizeRx positions in Q1 2026 and 30 closed out, a net change of -1 holder.
- The largest OptimizeRx buyer in Q1 2026 was Goldman Sachs, an estimated $2.15M added.
- The largest OptimizeRx seller in Q1 2026 was Next Century Growth Investors, an estimated $6.2M sold.
Based on aggregated 13F filings for Q1 2026.